Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Angelini-Industries"

3 News Found

ResMed acquires Noctrix Health for $340 million
Medical Device | June 04, 2026

ResMed acquires Noctrix Health for $340 million

Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
News | February 24, 2026

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support

EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups
Startup | December 03, 2025

EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups

Angelini Ventures has already invested €125 million in 22 startups

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Global clinical trials are shifting east. Is India ready to lead?

Merck names Miguel Alcalde to lead global commercial strategy; Monia Vial to head North America

Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Peptides are next frontline therapeutics led by GLP-1: Dr. Vandana Singh, Head - API Regulatory Sciences, Biocon Limited
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
Rising pharma demand driving our India market strategy: Sanjeev Kumar Khandelwal, Head of Division, Characterization Division, Anton Paar India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International

Packaging